1. HIV/AIDS communities and AIDS vaccine research AIDES / TRT-5 Tour Essor 14, rue Scandicci 93508 Pantin Cedex

2. Questions from the community  ANRS and vaccine trials of therapeutic vaccines  ANRS and recruitment of HIV- volunteers to participate to vaccine trials (safety issues raised)  Partnership with African NGOs (Réseau Afrique 2000): how far are we from a vaccine?  To stop the spread of AIDS

3. To be better informed  TRT-5 first met with the ANRS investigators (1999) Aventis (Alvac) in 1999  Attendance to scientific meetings  Internal training sessions (immunologists)

4. To inform (articles in our newsletters)

5. To inform (training sessions in Africa)

6. To inform (symposium on immunology)

7. To inform  Press releases after the announcement of the results of the ANRS trials  Press release after AIDSVAX results

8. To link up  Vaccine Working Group  IAVI partnership  Microbicides initiative

9. To work with  ANRS AC5 Clinical trials: to have two community representatives (voting rights) AC28 Preventive vaccines: two community representatives (one from the HIV community and one from the volunteers)  Modification of design of clinical trials  Set up of the long term follow up of vaccinees

10. To lobby  Towards the Industry to have access to vaccine preparation (Aventis supplied Orvéac with ALVAC after a TRT-5 meeting)  Authorities to maintain a strong commitment to prolong the ANRS  Within the ANRS, AC28 to finally do a proper work!

11. To lobby  Within our organization for preventive technologies to be a priority  EU for commitment  French government to pursue funding for a preventive vaccine. Does it have to be only directed to the ANRS?